The Only Meeting Focusing Solely on ADC Targets
Transforming ADC Target Selection by Identifying Novel & Repurposing Clinically Validated Targets to Develop First & Best-in-Class ADCs
Get the First Step of Your ADC Development Right & Explore the Current Target Landscape
The 2024 agenda will be released soon. If you are interested in this year's event, please get in touch at adc@hansonwade.com
With the number of new clinical ADC targets reaching an all-time high, the 4th ADC Target Selection Summit returns as the only meeting spotlighting the latest developments in target identification, selection and target specific ADC development that will continue progressing first- and best-in-class ADCs into and through the clinic.
Providing a greater focus on identifying and validating novel targets such as SEZ6, re-examining what makes a good target, and analyzing how novel linker-payload technologies such as topoisomerase I payloads are changing the target selection paradigm; this summit was your unique opportunity to delve into the use of proteomics to ensure you get the first step of drug development right.
This summit has joined 100+ of your peers from Iksuda Therapeutics, Merck &Co, Angiex, Ziel Bio, and Seagen; working in discovery, biology, target identification and validation. With three days of content carefully created to provide you with renewed strategic and scientific insights to progress your ADC pipelines for 2025 and beyond, this is a conversation not to miss.
‘Content was just excellent!’
Mablink
The 2023 World-Class Speaker Faculty Included:
‘Opportunities to network were fantastic’
Merck & Co
2024 Partners
About the World ADC Series:
The World ADC team ploughs its collective energy in to sourcing the insights you need. We investigate the most challenging problems facing the industry; source the leading experts who have game-changing solutions; and distil this into accessible formats of information exchange – for you. From globally leading conferences to webinars and industry reports, whatever the information you need, World ADC can offer you the insights you need to accelerate your ADC programs.
The value World ADC provides you is the power of insight and connections. Not artificial, and not short-lived. We nurture the right environments in which people can communicate problems and solutions; share novel data and forge networks across the industry that will make each of your endeavours more informed and more robust.
We share a common belief with the industry – that the potential of antibody drug conjugates is enormous. In the war against cancer, ADCs can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.
Join us at the heart of the ADC community to improve your programmes and be part of the mission to develop better antibody drug conjugate drugs.
